Holen Sie sich die Stockscreener-App
43.33
3.88%
1.62
Handel nachbörslich:
43.33
Schlusskurs vom Vortag:
$41.71
Offen:
$41.52
24-Stunden-Volumen:
200.62K
Relative Volume:
0.63
Marktkapitalisierung:
$3.28B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-17.40
EPS:
-2.49
Netto-Cashflow:
$-156.53M
1W Leistung:
+3.71%
1M Leistung:
+6.38%
6M Leistung:
-0.96%
1J Leistung:
+31.78%
1-Tages-Spanne:
$41.52
$43.36
1-Wochen-Bereich:
$40.66
$43.36
52-Wochen-Spanne:
$27.98
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon to Report Q3 2024 Financial Results on November 12, 2024 - StockTitan
Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
New Horizons in Tonic-clonic Seizure Market Exploring Future - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plc - MarketBeat
Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc. - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning - Defense World
Creative Planning Buys 2,475 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Assenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
When (XENE) Moves Investors should Listen - Stock Traders Daily
SG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Zacks Investment Research
Millennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE)’s Day in Review: Closing at 39.42, Down by -3.90 - The Dwinnex
Raymond James sets steady target on Xenon Pharmaceuticals By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Earns "Outperform" Rating from Raymond James - MarketBeat
Xenon Pharmaceuticals Inc Inc. (XENE) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Limbal Stem Cells Deficiency Market Enhanced Profitability, - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dimensional Fund Advisors LP Raises Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Analysts Offer Predictions for Xenon Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:XENE) - MarketBeat
Thrivent Financial for Lutherans Invests $1.68 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Top investors say Xenon Pharmaceuticals Inc (XENE) ticks everything they need - SETE News
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $39.37 - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Now Covered by HC Wainwright - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner trials key to stock's future By Investing.com - Investing.com South Africa
Xenon Pharmaceuticals' SWOT analysis: azetukalner trials key to stock's future - Investing.com
Point72 Asset Management L.P. Purchases 206,163 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is Driehaus Capital Management LLC's 6th Largest Position - MarketBeat
Marshall Wace LLP Cuts Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Kenvue Inc. (NYSE:KVUE) Stake Decreased by Pacer Advisors Inc. - Defense World
Pacer Advisors Inc. Purchases 12,698 Shares of Carrier Global Co. (NYSE:CARR) - Defense World
Pacer Advisors Inc. Sells 28 Shares of TopBuild Corp. (NYSE:BLD) - Defense World
Pacer Advisors Inc. Sells 20,524 Shares of PPL Co. (NYSE:PPL) - Defense World
Pacer Advisors Inc. Has $3.60 Million Position in AutoZone, Inc. (NYSE:AZO) - Defense World
Pacer Advisors Inc. Buys 1,185 Shares of Comfort Systems USA, Inc. (NYSE:FIX) - Defense World
PDD Holdings Inc. (NASDAQ:PDD) Position Increased by Pacer Advisors Inc. - Defense World
Pacer Advisors Inc. Sells 27,232 Shares of NVR, Inc. (NYSE:NVR) - Defense World
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director |
Mar 08 '24 |
Sale |
45.69 |
2,092 |
95,583 |
0 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Option Exercise |
9.85 |
8,641 |
85,114 |
16,824 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Sale |
46.28 |
7,137 |
330,290 |
8,398 |
| GANNON STEVEN | Director |
Mar 07 '24 |
Sale |
46.28 |
13,000 |
601,615 |
2,000 |
| AZAB MOHAMMAD | Director |
Dec 19 '23 |
Option Exercise |
9.85 |
4,320 |
42,552 |
74,225 |
| PATOU GARY | Director |
Dec 13 '23 |
Option Exercise |
9.55 |
14,402 |
137,487 |
29,951 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
39.29 |
11,380 |
447,085 |
23,573 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
41.05 |
7,598 |
311,898 |
4,902 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):